Plasma phospholipids, non-esterified plasma polyunsaturated fatty acids and oxylipids are associated with BMI

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 95, Issue , 2015, Pages 31-40

  Pickens, C Austin ^a   Sordillo, Lorraine M ^b   Comstock, Sarah S ^a   Harris, William S ^c   Hortos, Kari ^d   Kovan, Bruce ^d,e   Fenton, Jenifer I ^a  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e Tri County Gastroenterology Professional Corporation Clinton Tri County Gastroenterology Professional Corporation   (United States)

Author keywords

Biomarker; Human; Inflammation; Lipidome; Nervonic acid; Obesity

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; LINOLEIC ACID; LIPID; NERVONIC ACID; OMEGA 6 FATTY ACID; OXYLIPID; PALMITOLEIC ACID; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG; MONOUNSATURATED FATTY ACID; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC INFLAMMATION; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LEAN BODY WEIGHT; LIPID COMPOSITION; MALE; NORMAL HUMAN; OBESITY; OXIDATIVE STRESS; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; BLOOD; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PROCEDURES;

8,11,14-EICOSATRIENOIC ACID; AGED; BODY MASS INDEX; CHROMATOGRAPHY, GAS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, UNSATURATED; HUMANS; LINOLEIC ACID; MALE; MIDDLE AGED; OBESITY; TRIGLYCERIDES;

EID: 84924759330     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.12.001     Document Type: Article

References (63)

1. Emanuela F., Grazia M., Marco de R., Maria Paola L., Giorgio F., Marco B. Inflammation as a link between obesity and metabolic syndrome. J. Nutr. Metab. 2012, 2012:476380.
2. Yu M., Zhou H., Zhao J., Xiao N., Roychowdhury S., Schmitt D., Hu B., Harding C.V., Hise A.G., Hazen S.L., DeFranco A.L., Fox P.L., Morton R.E., Dicorleto P.E., Febbraio M., Nagy L.E., Smith J.D., Wang J.A., Li X. MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J. Exp. Med. 2014, 211:887-907.
3. Yoo H.J., Choi K.M. Adipokines as a novel link between obesity and atherosclerosis. World J. Diabetes 2014, 5:357-363.
4. Holland W.L., Knotts T.A., Chavez J.A., Wang L.P., Hoehn K.L., Summers S.A. Lipid mediators of insulin resistance. Nutr. Rev. 2007, 65:S39-46.
5. Ramsden C.E., Ringel A., Feldstein A.E., Taha A.Y., MacIntosh B.A., Hibbeln J.R., Majchrzak-Hong S.F., Faurot K.R., Rapoport S.I., Cheon Y., Chung Y.M., Berk M., Mann J.D. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot. Essent. Fatty Acids 2012, 87:135-141.
6. Zong G., Ye X., Sun L., Li H., Yu Z., Hu F.B., Sun Q., Lin X. Associations of erythrocyte palmitoleic acid with adipokines, inflammatory markers, and the metabolic syndrome in middle-aged and older Chinese. Am J. Clin. Nutr. 2012, 96:970-976.
7. Qu Q., Xuan W., Fan G. Roles of resolvins in the resolution of acute inflammation. Cell Biol. Int. 2014.
8. Volpe C.M., Nogueira-Machado J.A. The dual role of free fatty acid signaling in inflammation and therapeutics. Recent Pat. Endocr. Metab. Immune. Drug Discovery 2013, 7:189-197.
9. Keenan A.H., Pedersen T.L., Fillaus K., Larson M.K., Shearer G.C., Newman J.W. Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J. Lipid Res. 2012, 53:1662-1669.
10. Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., Konkel A., von Schacky C., Luft F.C., Muller D.N., Rothe M., Schunck W.H. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J. Biol. Chem. 2010, 285:32720-32733.
11. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
12. Mabalirajan U., Agrawal A., Ghosh B. 15-Lipoxygenase eicosanoids are the putative ligands for vanilloid receptors and peroxisome proliferator-activated receptors (PPARs). Proc. Nat. Acad. Sci. U.S.A. 2012, 109:E1. (author reply E2).
13. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495-505.
14. Raphael W., Sordillo L.M. Dietary polyunsaturated fatty acids and inflammation: the role of phospholipid biosynthesis. Int. J. Mol. Sci. 2013, 14:21167-21188.
15. Comstock S.S., Hortos K., Kovan B., McCaskey S., Pathak D.R., Fenton J.I. Adipokines and obesity are associated with colorectal polyps in adult males: a cross-sectional study. PLoS One 2014, 9:e85939.
16. Gurzell E.A., Wiesinger J.A., Morkam C., Hemmrich S., Harris W.S., Fenton J.I. Is the omega-3 index a valid marker of intestinal membrane phospholipid EPA+DHA content?. Prostaglandins Leukot. Essent. Fatty Acids 2014.
17. Rose H.G., Oklander M. Improved procedure for the extraction of lipids from human erythrocytes. J. Lipid Res. 1965, 6:428-431.
18. Agren J.J., Julkunen A., Penttila I. Rapid separation of serum lipids for fatty acid analysis by a single aminopropyl column. J. Lipid Res. 1992, 33:1871-1876.
19. Burdge G.C., Wright P., Jones A.E., Wootton S.A. A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br. J. Nutr. 2000, 84:781-787.
20. Mattmiller S.A., Carlson B.A., Gandy J.C., Sordillo L.M. Reduced macrophage selenoprotein expression alters oxidized lipid metabolite biosynthesis from arachidonic and linoleic acid. J. Nutr. Biochem. 2014, 25:647-654.
21. Y.y Multiple imputation using SAS software. J. Stat. Softw. 2011, 45.
22. Bursac Z., Gauss C.H., Williams D.K., Hosmer D.W. Purposeful selection of variables in logistic regression. Source Code Biol. Med. 2008, 3:17.
23. King T.M. Using simultaneous equation modeling for defining complex phenotypes. BMC Genet. 2003, 4(Suppl 1):S10.
24. Yamazaki Y., Kondo K., Maeba R., Nishimukai M., Nezu T., Hara H. The proportion of nervonic acid in serum lipids is associated with serum plasmalogen levels and metabolic syndrome. J. Oleo Sci. 2014, 63:527-537.
25. Deng Y., Scherer P.E. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. N.Y. Acad. Sci. 2010, 1212:E1-E19.
26. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
27. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
28. Glatz J.F., Luiken J.J., Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev. 2010, 90:367-417.
29. Perreault M., Zulyniak M.A., Badoud F., Stephenson S., Badawi A., Buchholz A., Mutch D.M. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One 2014, 9:e88539.
30. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front. Biosci. 1998, 3:d169-175.
31. Leamy A.K., Egnatchik R.A., Young J.D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog. Lipid Res. 2013, 52:165-174.
32. Bjermo H., Riserus U. Role of hepatic desaturases in obesity-related metabolic disorders. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:703-708.
33. Ntambi J.M., Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog. Lipid Res. 2004, 43:91-104.
34. Sauma L., Stenkula K.G., Kjolhede P., Stralfors P., Soderstrom M., Nystrom F.H. PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 2006, 22:60-68.
35. Stefan N., Peter A., Cegan A., Staiger H., Machann J., Schick F., Claussen C.D., Fritsche A., Haring H.U., Schleicher E. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008, 51:648-656.
36. Hulver M.W., Berggren J.R., Carper M.J., Miyazaki M., Ntambi J.M., Hoffman E.P., Thyfault J.P., Stevens R., Dohm G.L., Houmard J.A., Muoio D.M. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab. 2005, 2:251-261.
37. Park J.Y., Kim M.J., Kim Y.K., Woo J.S. Ceramide induces apoptosis via caspase-dependent and caspase-independent pathways in mesenchymal stem cells derived from human adipose tissue. Arch. Toxicol. 2011, 85:1057-1065.
38. Yuyama K., Mitsutake S., Igarashi Y. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease. Biochim. Biophys. Acta 1841, 2014:793-798.
39. Haus J.M., Kashyap S.R., Kasumov T., Zhang R., Kelly K.R., Defronzo R.A., Kirwan J.P. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009, 58:337-343.
40. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001, 15:719-730. (official publication of the Federation of American Societies for Experimental Biology).
41. Muthing J., Peter-Katalinic J., Hanisch F.G., Unland F., Lehmann J. The ganglioside GD1 alpha' IV3Neu5Ac, III6Neu5Ac-GgOse4Cer, is a major disialoganglioside in the highly metastatic murine lymphoreticular tumour cell line MDAY-D2. Glycoconj. J. 1994, 11:153-162.
42. Ladisch S., Li R., Olson E. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc. Nat. Acad. Sci. U.S.A. 1994, 91:1974-1978.
43. Popa I., Pons A., Mariller C., Tai T., Zanetta J.P., Thomas L., Portoukalian J. Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors. Glycobiology 2007, 17:367-373.
44. Tiberti C., Dotta F., Anastasi E., Torresi P., Multari G., Vecci E., Andreani D., Di Mario U. Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. Autoimmunity 1995, 22:43-48.
45. Hodge A.M., English D.R., O'Dea K., Sinclair A.J., Makrides M., Gibson R.A., Giles G.G. Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: interpreting the role of linoleic acid. Am. J. Clin. Nutr. 2007, 86:189-197.
46. Kroger J., Schulze M.B. Recent insights into the relation of Delta5 desaturase and Delta6 desaturase activity to the development of type 2 diabetes. Curr. Opin. Lipidol. 2012, 23:4-10.
47. Garcia-Webb P., Zimmet P., Bonser A., King H., Bottomley S. Factors affecting fasting serum C-peptide levels in Micronesians: comparison with a Caucasoid population. Diabetologia 1984, 27:23-26.
48. Harnack K., Andersen G., Somoza V. Quantitation of alpha-linolenic acid elongation to eicosapentaenoic and docosahexaenoic acid as affected by the ratio of n6/n3 fatty acids. Nutr. Metab. (Lond) 2009, 6:8.
49. Goyens P.L., Spilker M.E., Zock P.L., Katan M.B., Mensink R.P. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am. J. Clin. Nutr. 2006, 84:44-53.
50. Liou Y.A., King D.J., Zibrik D., Innis S.M. Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J. Nutr. 2007, 137:945-952.
51. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., Kuriyama H., Hotta K., Nakamura T., Shimomura I., Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
52. Mirzaei K., Hossein-Nezhad A., Keshavarz S.A., Koohdani F., Saboor-Yaraghi A.A., Hosseini S., Eshraghian M.R., Djalali M. Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects. Diabetol. Metab. Syndr. 2013, 5:79.
53. Altmann R., Hausmann M., Spottl T., Gruber M., Bull A.W., Menzel K., Vogl D., Herfarth H., Scholmerich J., Falk W., Rogler G. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. Biochem. Pharmacol. 2007, 74:612-622.
54. Shishehbor M.H., Zhang R., Medina H., Brennan M.L., Brennan D.M., Ellis S.G., Topol E.J., Hazen S.L. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radical Biol. Med. 2006, 41:1678-1683.
55. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
56. Tsai I.J., Croft K.D., Mori T.A., Falck J.R., Beilin L.J., Puddey I.B., Barden A.E. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. Free Radical Biol. Med. 2009, 46:263-270.
57. Wada K., Arita M., Nakajima A., Katayama K., Kudo C., Kamisaki Y., Serhan C.N. Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J. 2006, 20:1785-1792. (official publication of the Federation of American Societies for Experimental Biology).
58. Das U.N. Arachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules. Prostaglandins Leukot. Essent. Fatty Acids 2013, 88:201-210.
59. Soumya S.J., Binu S., Helen A., Reddanna P., Sudhakaran P.R. 15(S)-HETE-induced angiogenesis in adipose tissue is mediated through activation of PI3K/Akt/mTOR signaling pathway. Biochem. Cell Biol. 2013, 91:498-505.
60. Trayhurn P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu. Rev. Nutr. 2014.
61. Suzuki S., Oguro A., Osada-Oka M., Funae Y., Imaoka S. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J. Pharmacol. Sci. 2008, 108:79-88.
62. Dalli J., Serhan C.N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012, 120:e60-72.
63. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011, 121:2111-2117.